Loading patent…
AssigneeThe Regents of the University of California
InventorsVanessa DUNNE-CASTAGNA, David MILLS, J. Bruce GERMAN
Estimating the term…
The combination of specific immunoglobulins plus activated Bifidobacteria strains or other beneficial bacteria is described with the designed efficacy to colonize unstable microbiome communities in humans or other animals, restoring the keystone Bifidobacteria strains or other beneficial bacteria to compositional and functional importance in the intestine and improve overall health and reduce pathogenic infections in the host. Secretory immunoglobulin A (SIgA), when bound via specific glycans to select commensal bacteria grown on human milk oligosaccharides (HMOs), enhances the colonization potential of commensals through protection from intestinal digestion, enhancing attachment, and dampening host immune response.
A method of stimulating Bifidobacterium persistence or viability in the intestinal microbiome of an individual, the method comprising, administering a composition comprising a Bifidobacterium and a glycosylated immunoglobulin to the individual.
The method of any of the above claims, wherein the immunoglobulin and the Bifidobacterium form an immunoglobulin-Bifidobacterium complex prior to administration.
The method of any of the above claims, wherein the composition of Bifidobacterium and immunoglobulin are components of a food product or a pharmaceutical composition.
The method of any of the above claims, further comprising administering one or more polysaccharide to the individual in a sufficient amount to enhance colonization of the gut by the Bifidobacterium compared to not administering the polysaccharide.
The method of any of the above claims, further comprising administering one or more oligosaccharide to the individual in a sufficient amount to enhance colonization of the gut by the Bifidobacterium compared to not administering the oligosaccharide.
The method of any of the above claims, wherein the composition further comprises a Lactobacillus, wherein the Lactobacillus is selected from the group consisting of L. acidophilus, L. rhamnosus, L. casei, L. paracasei, L. plantarum and L. reuteri.
A pharmaceutical composition or food product comprising Bifidobacterium and an immunoglobulin in a dose sufficient to enhance colonization of the Bifidobacterium compared to administration of the Bifidobacterium alone.
A composition of 25, wherein the immunoglobulin is glycosylated.
The method of administering the composition or performing the method of any preceding claim, wherein administration is performed to treat or prevent a condition or disease.
The method of any of the above claims, wherein the individual is a human or non-human mammal.
A method of making an immunoglobulin-bacteria complex, comprising
Dependencies are inferred from the claim text.